These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9515577)

  • 61. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
    Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
    Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
    Voeller DM; Grem JL; Pommier Y; Paull K; Allegra CJ
    Cancer Chemother Pharmacol; 2000; 45(5):409-16. PubMed ID: 10803925
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
    Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
    Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
    Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
    Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Irinotecan in the treatment of colorectal cancer.
    Fuchs C; Mitchell EP; Hoff PM
    Cancer Treat Rev; 2006 Nov; 32(7):491-503. PubMed ID: 16959432
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S; Rustum YM
    Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells.
    Kondo T; Ueda K; Kano E
    Anticancer Res; 1995; 15(1):83-6. PubMed ID: 7733646
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.
    Peters GJ; Smid K; Meijer E; van Groeningen CJ; Leon LG
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):595-603. PubMed ID: 27906628
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.
    Mariadason JM; Arango D; Shi Q; Wilson AJ; Corner GA; Nicholas C; Aranes MJ; Lesser M; Schwartz EL; Augenlicht LH
    Cancer Res; 2003 Dec; 63(24):8791-812. PubMed ID: 14695196
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
    Paradiso A; Xu J; Mangia A; Chiriatti A; Simone G; Zito A; Montemurro S; Giuliani F; Maiello E; Colucci G
    Int J Cancer; 2004 Aug; 111(2):252-8. PubMed ID: 15197779
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
    Jones CB; Clements MK; Wasi S; Daoud SS
    Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
    Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
    Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
    Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
    Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
    Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.